Compare CRDF & IDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRDF | IDN |
|---|---|---|
| Founded | 1999 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.8M | 73.5M |
| IPO Year | 2012 | 2014 |
| Metric | CRDF | IDN |
|---|---|---|
| Price | $0.85 | $3.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $9.63 | $7.33 |
| AVG Volume (30 Days) | ★ 1.6M | 199.4K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 27.37 | ★ 220.00 |
| EPS | N/A | ★ 0.03 |
| Revenue | $365,993.00 | ★ $4,433,454.00 |
| Revenue This Year | N/A | $12.54 |
| Revenue Next Year | N/A | $15.32 |
| P/E Ratio | ★ N/A | $123.83 |
| Revenue Growth | ★ 49.61 | 23.21 |
| 52 Week Low | $0.76 | $3.59 |
| 52 Week High | $3.31 | $9.08 |
| Indicator | CRDF | IDN |
|---|---|---|
| Relative Strength Index (RSI) | 27.50 | 35.73 |
| Support Level | N/A | N/A |
| Resistance Level | $2.03 | $4.49 |
| Average True Range (ATR) | 0.07 | 0.16 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 7.93 | 19.84 |
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
Intellicheck Inc is a trusted industry leader in technology solutions that stop identity theft and fraud with real-time identification authentication and age verification. The group delivers on-demand digital and physical identity verification solutions for KYC, AML, fraud prevention, and age verification needs. The products of the company includes solutions for preventing identity fraud across any industry delivered via smartphone, tablet, POS integration or other electronic devices.